{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:26:54Z","timestamp":1761514014894,"version":"3.37.3"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2017,5,26]],"date-time":"2017-05-26T00:00:00Z","timestamp":1495756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1038\/cgt.2017.19","type":"journal-article","created":{"date-parts":[[2017,5,26]],"date-time":"2017-05-26T10:20:23Z","timestamp":1495794023000},"page":"358-360","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["An AAVP-based solid-phase transducing matrix for transgene delivery: potential for translational applications"],"prefix":"10.1038","volume":"24","author":[{"given":"T L","family":"Smith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G R","family":"Souza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R L","family":"Sidman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W","family":"Arap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4155-9324","authenticated-orcid":false,"given":"R","family":"Pasqualini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,5,26]]},"reference":[{"key":"BFcgt201719_CR1","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.cell.2006.02.042","volume":"125","author":"A Hajitou","year":"2006","unstructured":"Hajitou A, Trepel M, Lilley CE, Soghomonyan S, Alauddin MM, Marini FC 3rd et al. A hybrid vector for ligand-directed tumor targeting and molecular imaging. Cell 2006; 125: 385\u2013398.","journal-title":"Cell"},{"key":"BFcgt201719_CR2","doi-asserted-by":"publisher","first-page":"4471","DOI":"10.1073\/pnas.0712184105","volume":"105","author":"A Hajitou","year":"2008","unstructured":"Hajitou A, Lev DC, Hannay JA, Korchin B, Staquicini FI, Soghomonyan S et al. A preclinical model for predicting drug response in soft-tissue sarcoma with targeted AAVP molecular imaging. Proc Natl Acad Sci USA 2008; 105: 4471\u20134476.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFcgt201719_CR3","doi-asserted-by":"publisher","first-page":"e4972","DOI":"10.1371\/journal.pone.0004972","volume":"4","author":"MC Paoloni","year":"2009","unstructured":"Paoloni MC, Tandle A, Mazcko C, Hanna E, Kachala S, Leblanc A et al. Launching a novel preclinical infrastructure: comparative oncology trials consortium directed therapeutic targeting of TNFalpha to cancer vasculature. PLoS ONE 2009; 4: e4972.","journal-title":"PLoS ONE"},{"key":"BFcgt201719_CR4","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1073\/pnas.1525709113","volume":"113","author":"TL Smith","year":"2016","unstructured":"Smith TL, Yuan Z, Card\u00f3-Vila M, Sanchez Claros C, Adem A, Cui MH et al. AAVP displaying octreotide for ligand-directed therapeutic transgene delivery in neuroendocrine tumors of the pancreas. Proc Natl Acad Sci USA 2016; 113: 2466\u20132471.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFcgt201719_CR5","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1172\/JCI44798","volume":"121","author":"FI Staquicini","year":"2011","unstructured":"Staquicini FI, Ozawa MG, Moya CA, Driessen WH, Barbu EM, Nishimori H et al. Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma. J Clin Invest 2011; 121: 161\u2013173.","journal-title":"J Clin Invest"},{"key":"BFcgt201719_CR6","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1002\/cncr.24001","volume":"115","author":"A Tandle","year":"2009","unstructured":"Tandle A, Hanna E, Lorang D, Hajitou A, Moya CA, Pasqualini R et al. Tumor vasculature-targeted delivery of tumor necrosis factor-alpha. Cancer 2009; 115: 128\u2013139.","journal-title":"Cancer"},{"key":"BFcgt201719_CR7","doi-asserted-by":"publisher","first-page":"12786","DOI":"10.1073\/pnas.1615400113","volume":"113","author":"F Ferrara","year":"2016","unstructured":"Ferrara F, Staquicini DI, Driessen WHP, D'Angelo S, Dobroff AS, Barry M et al. Targeted molecular-genetic imaging and ligand-directed therapy in aggressive variant prostate cancer. Proc Natl Acad Sci USA 2016; 113: 12786\u201312791.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFcgt201719_CR8","doi-asserted-by":"publisher","first-page":"12780","DOI":"10.1073\/pnas.1615288113","volume":"113","author":"AS Dobroff","year":"2016","unstructured":"Dobroff AS, D'Angelo S, Eckhardt BL, Ferrara F, Staquicini DI, Cardo-Vila M et al. Towards a transcriptome-based theranostic platform for unfavorable breast cancer phenotypes. Proc Natl Acad Sci USA 2016; 113: 12780\u201312785.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFcgt201719_CR9","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1073\/pnas.0509739103","volume":"103","author":"GR Souza","year":"2006","unstructured":"Souza GR, Christianson DR, Staquicini FI, Ozawa MG, Snyder EY, Sidman RL et al. Networks of gold nanoparticles and bacteriophage as biological sensors and cell-targeting agents. Proc Natl Acad Sci USA 2006; 103: 1215\u20131220.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFcgt201719_CR10","doi-asserted-by":"publisher","first-page":"e2242","DOI":"10.1371\/journal.pone.0002242","volume":"3","author":"GR Souza","year":"2008","unstructured":"Souza GR, Yonel-Gumruk E, Fan D, Easley J, Rangel R, Guzman-Rojas L et al. Bottom-up assembly of hydrogels from bacteriophage and Au nanoparticles: the effect of cis- and trans-acting factors. PLoS ONE 2008; 3: e2242.","journal-title":"PLoS ONE"},{"key":"BFcgt201719_CR11","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/nnano.2010.23","volume":"5","author":"GR Souza","year":"2010","unstructured":"Souza GR, Molina JR, Raphael RM, Ozawa MG, Stark DJ, Levin CS et al. Three-dimensional tissue culture based on magnetic cell levitation. Nat Nanotechnol 2010; 5: 291\u2013296.","journal-title":"Nat Nanotechnol"},{"key":"BFcgt201719_CR12","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1073\/pnas.1525796113","volume":"113","author":"H Hosoya","year":"2016","unstructured":"Hosoya H, Dobroff AS, Driessen WH, Cristini V, Brinker LM, Staquicini FI et al. Integrated nanotechnology platform for tumor-targeted multimodal imaging and therapeutic cargo release. Proc Natl Acad Sci USA 2016; 113: 1877\u20131882.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFcgt201719_CR13","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nprot.2007.51","volume":"2","author":"A Hajitou","year":"2007","unstructured":"Hajitou A, Rangel R, Trepel M, Soghomonyan S, Gelovani JG, Alauddin MM et al. Design and construction of targeted AAVP vectors for mammalian cell transduction. Nat Protoc 2007; 2: 523\u2013531.","journal-title":"Nat Protoc"},{"key":"BFcgt201719_CR14","doi-asserted-by":"publisher","first-page":"35849","DOI":"10.1074\/jbc.M112.369389","volume":"287","author":"CA Stoneham","year":"2012","unstructured":"Stoneham CA, Hollinshead M, Hajitou A . Clathrin-mediated endocytosis and subsequent endo-lysosomal trafficking of adeno-associated virus\/phage. J Biol Chem 2012; 287: 35849\u201335859.","journal-title":"J Biol Chem"},{"key":"BFcgt201719_CR15","doi-asserted-by":"publisher","first-page":"6232","DOI":"10.1021\/ac060483a","volume":"78","author":"GR Souza","year":"2006","unstructured":"Souza GR, Levin CS, Hajitou A, Pasqualini R, Arap W, Miller JH . In vivo detection of gold-imidazole self-assembly complexes: NIR-SERS signal reporters. Anal Chem 2006; 78: 6232\u20136237.","journal-title":"Anal Chem"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/cgt201719.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/cgt201719","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/cgt.2017.19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/cgt201719.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:14:15Z","timestamp":1684415655000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/cgt201719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,26]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["BFcgt201719"],"URL":"https:\/\/doi.org\/10.1038\/cgt.2017.19","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"type":"print","value":"0929-1903"},{"type":"electronic","value":"1476-5500"}],"subject":[],"published":{"date-parts":[[2017,5,26]]},"assertion":[{"value":"23 February 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"GRS serves as President and Chief Scientific Officer and has equity in Nano3D Biosciences. WA and RP are founders of AAVP BioSystems, which has licensed intellectual property related to the adeno-associated virus\/phage (AAVP) technology, and they are inventors on patent applications and entitled to standard royalties if commercialization occurs. The University of New Mexico Health Sciences Center currently manages these arrangements in accordance with its established institutional conflict of interest policy. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}